Latest Conference Articles

Carmelo Carlo-Stella, MD

Treatment with ibrutinib plus loncastuximab tesirine-lpyl resulted in high objective and complete response rates and an acceptable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from an interim analysis of the phase 1/2 LOTIS-3 trial (NCT03684694) that were presented at the 2021 ASH Annual Meeting and Exposition.

Komal Jhaveri, MD

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.